tradingkey.logo

Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

ReutersApr 3, 2025 11:35 AM

- Intellia Therapeutics Inc NTLA.O:

  • INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY

  • INTELLIA THERAPEUTICS INC: PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI